- H90 -

In The News The NIMML Institute and NImmune Biopharma Announce Publication of New Mechanistic Insights on the Immunometabolic Control of Systemic Lupus Erythematosus in the Journal of Immunology NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024 the Annual Meeting of the American Association of Immunologists NIMML Institutes TITANX A. I. Powered Precision Medicine Platform Validated through AbbVies Acquisition of Landos Biopharma and Lead Clinical Candidate NX13 Translational and Clinical Science The NIMML Institute and NImmune Biopharma Announce Publication of Positive FirstinHuman Data of NIM1324 a Phase 2 Candidate for Systemic Lupus Erythematosus in Clinical and Translational Science NIMML Presents Positive FirstinHuman Data of NIM1324 a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 ACR23 NIMML Announces Positive Results of Omilancor Clinical Trials in Ulcerative Colitis and Crohns Disease at the American College of Gastroenterology 2023 Annual Scientific Meeting Entrepreneurship NIMML Institute and NImmune Biopharma Partner to Advance Precision Medicine Research for Autoimmune Diseases The NIMML Institute Founder Launches NImmune Biopharma to Develop LateStage Breakthrough Immunoregulatory Medicines for Autoimmune Diseases Landos Biopharma to Present at the 38th Annual J. P.